Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06042205

TISSIUM™ Atraumatic Hernia Repair System (TAHRS) Pilot Study

The purpose of this study is to capture preliminary clinical safety and performance on the TAHRS

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Ziekenhuis Oost-Limburg [ZOL], Genk, Limburg, Belgium

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • Subject is 18 years old or older;
  • Patient willing and able to provide a signed Patient Informed Consent Form;
  • Has a midline primary ventral, umbilical or incisional hernia;
  • Scheduled for a laparoscopic IPOM hernia repair;
  • Hernia can be successfully repaired with at least a 5 cm overlap of the mesh on all sides of the defect

Key Exclusion Criteria:

  • Patient has a known or suspected hypersensitivity to the constituent polymer of the investigational device, mesh, or other surgical products (e.g., sutures);
  • BMI > 40;
  • Patient is a current smoker, defined as self-reporting smoking more than 1 cigarette per day;
  • Patient is taking systemic immunosuppressive medications, systemic steroids, or chemotherapy at the time of informed consent;
  • Patient is pregnant, plans to become pregnant during the study period, or is breastfeeding;
  • Patient with Type 1 or uncontrolled Type 2 Diabetes Mellitus;
  • Patient has more than one hernia defect (to be confirmed intraoperatively);

Treatment and study plan

TISSIUM™ Atraumatic Hernia Repair System (TAHRS)

Device

The TAHRS is intended for fixation of prosthetic material to soft tissue

Primary outcomes

  1. Serious Adverse Device Effect (SADEs)

    Time frame: through 12 months post-surgery

    Cumulative incidence of complications (CIC) related to the TAHRS including:

    Infection, Chronic pain, Recurrence of hernia, Impaired/delayed healing at the surgical site(s), Allergic reaction/hypersensitivity reaction,

Secondary outcomes

  1. Rate of hernia recurrence through 12 months post- surgery

    Time frame: through 12 months post-surgery

Sponsors and collaborators

Lead sponsor

Tissium

Industry

Registry information

Official study title

ALPHA: A Pilot Study to Evaluate the Initial Safety and Performance of the TISSIUM™ Atraumatic Hernia Repair System (TAHRS) for Laparoscopic Hernia Repair

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Sep 18, 2023
Registry last updated
Jul 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.